Amelioration of anemia in the ICGN mouse, a renal anemia model, with a subcutaneous bolus injection of erythropoietin adsorbed to hydroxyapatite matrix

Journal of Veterinary Medical Science

Volumn 71, Issue 10, 2009, Pages 1365-1371

  Nagasaki, Ken Ichi ^a,b   Ikoma, Toshiyuki ^c   Katsuda, Shin Ichi ^b   Tonegawa, Toru ^d   Tanaka, Junzo ^d   Ohyama, Minami ^b   Hayashida, Kosuke ^b   Nakamura, Teppei ^b   Sato, Hidetaka ^b   Ito, Shigeo ^e   Sasaki, Nobuya ^a   Agui, Takashi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b JAPAN FOOD RESEARCH LABORATORIES   (Japan)

^c NATIONAL INSTITUTE FOR MATERIALS SCIENCE   (Japan)

^d TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^e HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Drug delivery system; Erythropoietin; Hydroxyapatite; ICGN mice; Renal anemia

Indexed keywords

ERYTHROPOIETIN; HYDROXYAPATITE; RECOMBINANT PROTEIN;

ANEMIA; ANIMAL; ARTICLE; CHEMISTRY; DELAYED RELEASE FORMULATION; GERMFREE ANIMAL; GLOMERULONEPHRITIS; HUMAN; MOUSE; MOUSE STRAIN; TIME;

ANEMIA; ANIMALS; DELAYED-ACTION PREPARATIONS; DURAPATITE; ERYTHROPOIETIN; GLOMERULONEPHRITIS; HUMANS; MICE; MICE, INBRED STRAINS; RECOMBINANT PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS; TIME FACTORS;

MUS;

EID: 70350662575     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.001365     Document Type: Article

References (34)

1. Adamson, J. W. and Eschbach, J. W. 1990. Treatment of the anemia of chronic renal failure with recombinant human erythropoietin. Annu. Rev. Med. 41: 349-360.
2. Chai, F., Hornez, J. C., Blanchemain, N., Neut, C., Descamps, M. and Hildebrand, H. F. 2007. Antibacterial activation of hydroxyapatite (HA) with controlled porosity by different antibiotics. Biomol. Eng. 24: 510-514.
3. Cho, A. R., Uchio-Yamada, K., Torigai, T., Miyamoto, T., Miyoshi, I., Matsuda, J., Kurosawa, T., Kon, Y., Asano, A., Sasaki, N. and Agui, T. 2006. Deficiency of the tensin2 gene in the ICGN mouse: an animal model for congenital nephrotic syndrome. Mamm. Genome 17: 407-416.
4. Elbert, D. L., Pratt, A. B., Lutolf, M. P., Halstenberg, S. and Hubbell, J. A. 2001. Protein delivery from materials formed by self-selective conjugate addition reactions. J. Controll. Release 76: 11-25.
5. Fu, K., Klibanov, A. M. and Langer, R. 2000. Protein stability in controlled-release systems. Nat. Biothechnol. 18: 24-25.
6. Gautier, H., Guicheux, J., Grimandi, G., Faivre-Chauvet, A., Daculsi, G. and Merle, C. 1998. In vitro influence of apatitegranule-specific area on human growth hormone loading and release. J. Biomed. Mater. Res. 40: 606-613.
7. Geng, Y., Yuan, W., Wu, F., Chen, J., He, M. and Jin, T. 2008. Formulating erythropoietin-loaded sustained-release PLGA microspheres without protein aggregation. J. Controll. Release 130: 259-265.
8. Guicheux, J., Grimandi, G., Trécant, M., Faivre, A., Takahashi, S. and Daculsi, G. 1997. Apatite as carrier for growth hormone: in vitro characterization of loading and release. J. Biomed. Mater. Res. 34: 165-170.
9. Hahn, S. K., Oh, E. J., Miyamoto, H. and Shimobouji, T. 2006. Sustained release formulation of erythropoietin using hyaluronic acid hydrogels crosslinked by Michael addition. Int. J. Pharm. 322: 44-51.
10. Ito, Y., Shiroyama, K., Yoshimitsu, J., Ohashi, Y., Sugioka, N. and Takada, K. 2007. Pharmacokinetic and pharmacodynamic studies following percutaneous absorption of erythropoietin micropiles to rats. J. Controll. Release 121: 176-180.
11. Itokazu, M., Sugiyama, T., Ohno, T., Wada, E. and Katagiri, Y. 1998. Development of porous apatite ceramic for local delivery of chemotherapeutic agents. J. Biomed. Mater. Res. 39: 536-538.
12. Jacobs, C., Hörl, W. H., Macdougall, I. C., Valderrábano, F., Parrondo, I., Abraham, I. L. and Segner, A. 2000. European best practice guidelines 9-13: anaemia management. Nephrol. Dial. Transplant. 15: 33-42.
13. Kim, H. W., Knowles, J. C. and Kim, H. E. 2004. Development of hydroxyapatite bone scaffold for controlled drug release via poly(epsilon-caprolactone) and hydroxyapatite hybrid coatings. J. Biomed. Mater. Res. B Appl. Biomater. 15: 240-249.
14. Krantz, S. B. 1991. Erythropoietin. Blood 77: 419-434
15. Lacombe, C., Da Silva, J. L., Bruneval, P., Fournier, J. G., Wendling, F., Casadevall, N., Camilleri, J. P., Bariety, J., Varet, B. and Tambourin, P. 1988. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J. Clin. Invest. 81: 620-623.
16. Lin, X., Fujita, M., Kanemitsu, N., Kimura, Y., Tambara, K., Premaratne, G. U., Nagasawa, A., Ikeda, T., Tabata, Y. and Komeda, M. 2007. Sustained-release erythropoietin ameliorates cardiac function in infarcted rat-heart without inducing polycythemia. Circ. J. 71: 132-137.
17. Masuda, S., Okano, M., Yamagishi, K., Nagao, M., Ueda, M. and Ssaki, R. 1994. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J. Biol. Chem. 269: 19488-19493.
18. Matsumoto, T., Okazaki, M., Inoue, M., Yamaguchi, S., Kusunose, T., Toyonaga, T., Hamada, Y. and Takahashi, J. 2004. Hydroxyapatite particles as a controlled release carrier of protein. Biomaterials 25: 3807-3812.
19. Miyamoto, Y., Kuramitsu-Miyamoto, K., Iwanaga, E., Uchio-Yamada, K., Yamaguchi-Yamada, M., Ogura, A. and Manabe, N. 2005. Effect of human erythropoietin (hEPO) treatment on anemia in ICR-derived glomerulonephritis (ICGN) mice. Exp. Anim. 54: 181-184.
20. Mizuno, S., Mizuno-Horikawa, Y., Yue, B. F., Okamoto, M. and Kurosawa, T. 1999. Nephrotic mice (ICGN strain): a model of diffuse mesangial sclerosis in infantile nephrotic syndrome. Am. J. Nephrol. 19: 73-82.
21. Mizushima, Y., Ikoma, T., Tanaka, J., Hoshi, K., Ishihara, T., Ogawa, Y. and Ueno, A. 2006. Injectable porous hydroxyapatite microparticles as a new carrier for protein and lipophilic drugs. J. Controll. Release 110: 260-265.
22. Morlock, M., Kissel, T., Li, Y. X, Koll, H and Winter, G. Erythropoietin loaded microspheres prepared from biodegradable LPLG-PEO-LPLG triblock copolymers: protein stabilization and in-vitro release properties. 1998. J. Controll. Release 56: 105-115.
23. Motokawa, K., Hahn, S. K., Nakamura, T., Miyamoto, H. and Shimoboji, T. 2006. Selectively crosslinked hyaluronic acid hydrogels for sustained release formulation of erythropoietin. J. Biomed. Mater. Res. A 78: 459-465.
24. Nagao, T. and Goto, M. 2006 Yakuzaigaku. 66: 139-142 (in Japanese).
25. Nagasaki, K., Ikoma, T., Katsuda, S., Tonegawa, T., Tanaka, J., Nakamura, T., Sato, H., Ito, S., Sasaki, N. and Agui, T. 2009. Sustained efficacy of erythropoietin with a hydroxyapatite carrier administered in mice. J. Vet. Med. Sci. 71: 729-736.
26. Ogura, A., Asano, T., Matsuda, J., Takano, K., Nakagawa, M. and Fukui, M. 1989. Characteristics of mutant mice (ICGN) with spontaneous renal lesions: a new model for human nephrotic syndrome. Lab. Anim. 23: 169-174.
27. Qiu, B., Stefanos, S., Ma, J., Lalloo, A., Perry, B. A., Leibowitz, M. J., Sinko, P. J. and Stein, S. 2003. A hydrogel prepared by in situ cross-linking of a thiol-containing poly(ethylene glycol)-based copolymer: a new biomaterial for protein drug delivery. Biomaterials 24: 11-18.
28. Shinto, Y., Uchida, A., Korkusuz, F., Araki, N. and Ono, K. 1992. Calcium hydroxyapatite ceramic used as a delivery system for antibiotics. J. Bone Joint Surg. Br. 74: 600-604.
29. Sudo, A., Hasegawa, M., Fukuda, A. and Uchida, A. 2008. Treatment of infected hip arthroplasty with antibiotic-impregnated calcium hydroxyapatite. J. Arthroplasty 23: 145-150.
30. Vogel, J., Kiessling, I., Heinicke, K., Stallmach, T., Ossent, P., Vogel, O., Aulmann, M., Frietsch, T., Schmid-Schönbein, H., Kuschinsky, W. and Gassmann, M. 2003. Transgenic mice overexpressing erythropoietin adapt to excessive erythrocytosis by regulating blood viscosity. Blood 102: 2278-2284.
31. Yamaguchi-Yamada, M., Manabe, N., Goto, Y., Anan, S., Miyamoto, K., Miyamoto, Y., Nagao, M., Yamamoto, Y. and Ogura, A. 2004. Improvement of anemia associated with chronic renal failure by recombinant human erythropoietin treatment in ICR-derived glomerulonephritis (ICGN) mice. J. Vet. Med. Sci. 66: 883-886.
32. Yamaguchi-Yamada, M., Manabe, N., Uchio-Yamada, K., Akashi, N., Goto, Y., Miyamoto, Y., Nagao, M., Yamamoto, Y., Ogura, A. and Miyamoto, H. 2004. Anemia with chronic renal disorder and disrupted metabolism of erythropoietin in ICR-derived glomerulonephritis (ICGN) mice. J. Vet. Med. Sci. 66: 423-431
33. Yamamura, K., Iwata, H., Osada, T., Yotsuyanagi, T. and Nabeshima, T. 1994. Anticancer effects of adriamycin-loaded hydroxyapatite implants determined in a Swarm rat chondrosarcoma model. Jpn. J. Pharmacol. 65: 289-291.
34. Zhang, F., Gagnon, R. F., Richards, G. K. and Brox, A. G. 1996. Anemia of chronic renal failure: characterization in the mouse and correction with human recombinant erythropoietin. Nephron 72: 654-661.